| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049769296 |
| P356 | DOI | 10.2165/00003495-200060001-00004 |
| P698 | PubMed publication ID | 11129170 |
| P2093 | author name string | J Baselga | |
| S D Averbuch | |||
| P2860 | cites work | Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 |
| EGF receptor | Q28646107 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| Chemotherapy for non-small cell lung cancer: have we reached a new plateau? | Q33592725 | ||
| The epidermal growth factor receptor and its inhibition in cancer therapy | Q33716127 | ||
| Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experience | Q33897577 | ||
| The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. | Q33931614 | ||
| ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency | Q33963261 | ||
| Tyrosine kinases and their interactions with signalling proteins | Q36333766 | ||
| Growth factors and cancer | Q36441643 | ||
| Regulation of signal transduction and signal diversity by receptor oligomerization | Q40592846 | ||
| Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials | Q41718736 | ||
| Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). | Q42004592 | ||
| Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. | Q42812982 | ||
| Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor | Q57424632 | ||
| P304 | page(s) | 33-40; discussion 41-2 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | ZD1839 ('Iressa') as an anticancer agent | |
| P478 | volume | 60 Suppl 1 |
| Q44711407 | 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors |
| Q39168444 | A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance. |
| Q37423291 | A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer |
| Q40732059 | Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor |
| Q36005545 | Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer |
| Q28578050 | Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease |
| Q36673777 | Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells |
| Q35113656 | Advances in Molecular Therapies in Patients with Brain Tumors |
| Q40749244 | Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo |
| Q50111842 | Application of computational methods for anticancer drug discovery, design, and optimization. |
| Q46963924 | Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients |
| Q35548334 | Biologic directed therapies in gynecologic oncology |
| Q36552741 | Blockade of phospholipid scramblase 1 with its N-terminal domain antibody reduces tumorigenesis of colorectal carcinomas in vitro and in vivo |
| Q47417530 | CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer. |
| Q44541800 | Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. |
| Q34936052 | Clinical impact of novel treatment strategies |
| Q36565941 | Clinical implications of the mechanism of epidermal growth factor receptor inhibitors |
| Q48546612 | Comparative analysis of the surface interaction properties of the binding sites of CDK2, CDK4, and ERK2. |
| Q38743023 | Cordycepin Induces Apoptosis and Inhibits Proliferation of Human Lung Cancer Cell Line H1975 via Inhibiting the Phosphorylation of EGFR. |
| Q81232106 | Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1 |
| Q38288761 | Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. |
| Q36834883 | Drug Resistance to EGFR Inhibitors in Lung Cancer |
| Q37845248 | Drug therapy of cancer |
| Q36519010 | Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
| Q44306493 | EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor |
| Q37552436 | EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. |
| Q33811642 | ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. |
| Q39597821 | Effect of curcumin and irradiation in PE/CA-PJ15 oral squamous cell carcinoma |
| Q44483104 | Epidermal growth factor inhibitors |
| Q35162373 | Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. |
| Q39893964 | Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer |
| Q39752055 | Epidermal growth factor receptor signaling in nonsmall cell lung cancer |
| Q28141002 | Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy |
| Q34112979 | Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents |
| Q35038746 | Epithelial growth factor receptor interacting agents |
| Q38844092 | Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. |
| Q34684154 | Exploiting molecular targets in pancreatic cancer |
| Q24802613 | Finding the needle in the haystack: why high-throughput screening is good for your health |
| Q44122729 | Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor |
| Q34967095 | Gefitinib |
| Q38798293 | Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. |
| Q35562614 | Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer |
| Q53769683 | Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation. |
| Q37738913 | Gefitinib for the treatment of non-small-cell lung cancer. |
| Q35031807 | Gefitinib in non small cell lung cancer |
| Q33207883 | Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer |
| Q42013412 | Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics |
| Q92062026 | Golgi phosphoprotein 3 sensitizes the tumour suppression effect of gefitinib on gliomas |
| Q36061145 | HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. |
| Q37021815 | Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp |
| Q78339014 | How to combine cytotoxic and cytostatic agents |
| Q28472011 | Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data |
| Q37320501 | Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. |
| Q74449248 | Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin |
| Q44505555 | Induction of cytotoxicity and ssDNA breaks by 9-bromo-5-morpholino-tetrazolo[1,5-c]quinazoline in tumor cells cultured in vitro |
| Q41091349 | Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib |
| Q34928661 | Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors |
| Q41148890 | Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer |
| Q34792935 | Irreversible inhibitors of the erbB family of protein tyrosine kinases |
| Q24651229 | LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis |
| Q35790781 | Molecular biological design of novel antineoplastic therapies |
| Q34872645 | Molecular markers and therapeutic targets in ductal carcinoma in situ |
| Q34678359 | New drugs in gynecologic cancer |
| Q44117392 | New therapeutic targets and strategies in lung cancer |
| Q34498105 | Novel approaches to the treatment of non-small cell lung cancer. |
| Q35173073 | Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family |
| Q38110796 | Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. |
| Q34996001 | Novel techniques in the delivery of radiation in pediatric oncology |
| Q43461671 | Prognostic value of ERBB family mRNA expression in breast carcinomas |
| Q44415145 | Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures |
| Q78555013 | Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer |
| Q38292832 | Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach |
| Q36163978 | Review of current treatment practices for carcinoma of the head and neck |
| Q36051729 | Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China |
| Q39252267 | Synergic effect of curcumin or lycopene with irradiation upon oral squamous cell carcinoma cells |
| Q47742726 | Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinone analogues |
| Q40512067 | Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). |
| Q34878868 | Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action |
| Q34363419 | Targeted treatment of advanced and metastaticbreast cancer with lapatinib. |
| Q44120544 | Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth |
| Q36564975 | Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. |
| Q40158764 | The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines |
| Q38034347 | The promise of anti-ErbB3 monoclonals as new cancer therapeutics |
| Q39996855 | The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer. |
| Q34569395 | Therapy for stage IIIB and stage IV non-small cell lung cancer |
| Q43779719 | Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours |
| Q35589206 | Tyrosine kinase inhibitors as cancer therapy |
| Q35095147 | Tyrosine kinases as targets in cancer therapy - successes and failures |
| Q30482688 | Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers |
| Q79781049 | [Gefitinib-induced perforating dermatosis] |
| Q80554209 | [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology] |
| Q79788846 | [Skin signs associated with epidermal growth factor inhibitors] |
Search more.